Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$468M |
| 2 |
Johnson & Johnson
JNJ
|
+$440M |
| 3 |
IBM
IBM
|
+$355M |
| 4 |
Booking.com
BKNG
|
+$332M |
| 5 |
RAI
Reynolds American Inc
RAI
|
+$331M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LLTC
Linear Technology Corp
LLTC
|
+$482M |
| 2 |
Walt Disney
DIS
|
+$247M |
| 3 |
Visa
V
|
+$219M |
| 4 |
Deere & Co
DE
|
+$200M |
| 5 |
Johnson Controls International
JCI
|
+$179M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.02% |
| 2 | Technology | 13.31% |
| 3 | Financials | 12.25% |
| 4 | Industrials | 9.65% |
| 5 | Consumer Staples | 9.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GNVC
3126
DELISTED
GenVec, Inc.
GNVC
| $62K | ﹤0.01% |
10,260
-17,500
| -63% | -$109K |
|
3127
TROOPS Inc
TROO
$248M
| $60K | ﹤0.01% |
21,025
-1,800
| -8% | -$5.63K |
|
|
BDR
3128
DELISTED
Blonder Tongue Laboratories Inc
BDR
| $59K | ﹤0.01% |
101,000
+800
| +0.8% | +$540 |
|
|
DCTH
3129
DELISTED
Delcath Systems Inc
DCTH
| $59K | ﹤0.01% |
674,114
+513,986
| +321% | +$134K |
|
|
SHSP
3130
DELISTED
SharpSpring, Inc.
SHSP
| $58K | ﹤0.01% |
12,500
-7,100
| -36% | -$36.2K |
|
|
GRCE
3131
Grace Therapeutics
GRCE
$44.2M
| $57K | ﹤0.01% |
867
-71
| -8% | -$4.36K |
|
|
STAB
3132
DELISTED
Statera Biopharma, Inc. Common Stock
STAB
| $56K | ﹤0.01% |
35,016
+23,100
| +194% | +$38.3K |
|
3133
Digital Turbine
APPS
$1.5B
| $55K | ﹤0.01% |
58,964
+17,990
| +44% | +$14.1K |
|
3134
CF Bankshares
CFBK
$232M
| $55K | ﹤0.01% |
+4,655
| New | +$51.9K |
|
3135
IZEA Worldwide
IZEA
$53.8M
| $55K | ﹤0.01% |
+3,258
| New | +$56.8K |
|
|
ATIS
3136
DELISTED
Attis Industries Inc. Common Stock
ATIS
| $55K | ﹤0.01% |
+1,775
| New | +$42.3K |
|
|
TMQ
3137
Trilogy Metals
TMQ
$650M
| $53K | ﹤0.01% |
96,101
-29,200
| -23% | -$14.6K |
|
3138
Comstock Holding Companies
CHCI
$152M
| $52K | ﹤0.01% |
24,084
+5,300
| +28% | +$11.2K |
|
|
GMO
3139
DELISTED
General Moly, Inc.
GMO
| $52K | ﹤0.01% |
+103,600
| New | +$49.8K |
|
3140
XWELL
XWEL
$8.7M
| $51K | ﹤0.01% |
+20
| New | +$53.4K |
|
|
JRJR
3141
DELISTED
JRjr33, Inc.
JRJR
| $50K | ﹤0.01% |
111,100
+41,700
| +60% | +$28.7K |
|
|
AENZ
3142
DELISTED
Aenza S.A.A.
AENZ
| $49K | ﹤0.01% |
5,220
-100,210
| -95% | -$1.22M |
|
|
YGE
3143
DELISTED
Yingli Green Energy Holding Comp
YGE
| $49K | ﹤0.01% |
22,389
-27,000
| -55% | -$69K |
|
|
AGEN
3144
Agenus
AGEN
$311M
| $45K | ﹤0.01% |
+607
| New | +$48.1K |
|
|
TAT
3145
DELISTED
TransAtlantic Petroleum LTD.
TAT
| $45K | ﹤0.01% |
32,131
-1,820
| -5% | -$2.15K |
|
|
SSN
3146
DELISTED
Samson Oil & Gas Limited
SSN
| $45K | ﹤0.01% |
80,560
-16,700
| -17% | -$10.3K |
|
|
DMTX
3147
DELISTED
Dimension Therapeutics, Inc
DMTX
| $45K | ﹤0.01% |
25,900
-28,300
| -52% | -$75.1K |
|
3148
China Pharma Holdings
CPHI
$46.6M
| $44K | ﹤0.01% |
339
+72
| +27% | +$9.13K |
|
|
OSN
3149
DELISTED
Ossen Innovation Co., Ltd.
OSN
| $43K | ﹤0.01% |
20,833
-7,300
| -26% | -$15.9K |
|
3150
Mexco Energy
MXC
$20M
| $42K | ﹤0.01% |
10,900
-6,100
| -36% | -$27.8K |
|
Similar funds
Jim Simons's Q1 2017 Portfolio in Review
As of Q1 2017, Jim Simons held 3,652 positions worth $71.6B, up 13% from $63.2B the previous quarter. Its ten largest holdings account for 7.9% of the portfolio.
Jim Simons deployed $5.19B of net new capital in Q1 2017, opening 433 new positions and adding to 1,585 existing holdings. Its largest new stake was Merck: 7,716,460 shares worth $468M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, up from 12% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Walt Disney, an estimated $247M trimmed.
- Jim Simons's largest Q1 2017 buy was Merck: 7,716,460 shares worth $468M.
- Jim Simons added most to Johnson & Johnson in Q1 2017, an estimated $440M increase.
- Jim Simons's biggest Q1 2017 reduction was Walt Disney, cutting an estimated $247M.
- Jim Simons fully exited Linear Technology Corp in Q1 2017, selling an estimated $482M.
- Jim Simons's ten largest holdings make up 7.9% of its $71.6B portfolio in Q1 2017.
- Jim Simons opened 433 new positions and closed 462 in Q1 2017.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $71.6B.
Based on Renaissance Technologies's 13F filing for Q1 2017, filed 12 May 2017.